← Back to Search

Virus Therapy

Beta-glucan for Flu Vaccine Response (M-Unity Trial)

Phase 2
Waitlist Available
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have been immunized for COVID-19
Adult volunteers ≥ 50 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 days (day 1, day 14, day 15, and day 42)

Summary

This trial will test if a supplement can help the flu vaccine work better.

Who is the study for?
This trial is for healthy adults over 50 who plan to get the flu shot, can follow study procedures like blood draws and questionnaires, have had their COVID-19 shots, and can consent in English. It's not for those in other trials that might affect results, with severe vaccine reactions or immune system issues due to illness or treatments.
What is being tested?
The trial tests if beta-glucan (a fiber from baker's yeast) affects the body's response to the flu vaccine compared to a placebo. Participants will receive either beta-glucan or a dummy pill alongside their regular influenza vaccination.
What are the potential side effects?
Possible side effects may include typical responses to dietary supplements such as digestive discomfort. The flu vaccine itself may cause soreness at injection site, mild fever, or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have received the COVID-19 vaccine.
Select...
I am 50 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 days (day 1, day 14, day 15, and day 42)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 42 days (day 1, day 14, day 15, and day 42) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Antibody Titer
Secondary study objectives
Cold and flu symptoms
Fever
Incidence of influenza and Covid-19
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Beta-glucanExperimental Treatment2 Interventions
500 mg/day beta-glucan
Group II: PlaceboPlacebo Group2 Interventions
500 mg/day cellulose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Influenza Vaccine
2022
Completed Phase 4
~16570

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,395 Previous Clinical Trials
767,202 Total Patients Enrolled
Danstar Ferment AGUNKNOWN

Media Library

Influenza Vaccine (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05074303 — Phase 2
Healthy Aging Research Study Groups: Beta-glucan, Placebo
Healthy Aging Clinical Trial 2023: Influenza Vaccine Highlights & Side Effects. Trial Name: NCT05074303 — Phase 2
Influenza Vaccine (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05074303 — Phase 2
~28 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top